Medtronic Reports (PULSED AF) Trial Results of PulseSelect PFA System for Atrial Fibrillation
Shots:
- The (PULSED AF) pivotal trial evaluating PulseSelect System in 300 adult patients with a history of drug refractory, recurrent & symptomatic paroxysmal or persistent AF at 9 countries across 41 sites & 67 operators
- The system showed a low rate of primary safety AEs (0.7%) with no esophageal events, instances of pulmonary vein stenosis, or phrenic nerve injury
- Pulsed-field ablation was shown to be effective @1yr. in 66.2% with paroxysmal AF & 55.1% with persistent AF @12mos., freedom from atrial arrhythmia recurrence & symptomatic atrial arrhythmias was 70% & 80% in the paroxysmal; 62% & 81% in the persistent cohort. The results were presented at ACC.23/WCC & simultaneously published in Circulation
Ref: Medtronic | Image: Medtronic
Related Post:- Medtronic Reports One Year (ADAPT) Study Results of MiniMed 780G Advanced Hybrid Closed Loop System for Type 1 Diabetes
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
